Complete protection of Staphylococcus aureus Wood 46 from gentamicin bactericidal activity was documented for microorganisms located within polymorphonuclear leukocytes. The highest, still ineffective gentamicin concentration tested in the phagocytic assay was 80 times higher than the minimal concentration required to kill uningested organisms. Extracellular gentamicin activity was unaffected by the phagocytic process as demonstrated by microbiological and enzymatic assays, and liberation of intracellular S. aureus by lysis of neutrophils showed the bacteria to be fully susceptible to the antibiotic. These results were corroborated by studies performed with ['4C]gentamicin; binding of the labeled antibiotic by resting neutrophils, or by neutrophils ingesting live, killed S. aureus or endotoxin-coated paraffin particles, showed no statistical differences and never exceeded 20% of the extracellular concentration. These results show that intraleukocytic S. aureus are protected from the bactericidal action of gentamicin and suggest that this protection can be explained by poor intracellular penetration of the antibiotic.
Complete protection of Staphylococcus aureus Wood 46 from gentamicin bactericidal activity was documented for microorganisms located within polymorphonuclear leukocytes. The highest, still ineffective gentamicin concentration tested in the phagocytic assay was 80 times higher than the minimal concentration required to kill uningested organisms. Extracellular gentamicin activity was unaffected by the phagocytic process as demonstrated by microbiological and enzymatic assays, and liberation of intracellular S. aureus by lysis of neutrophils showed the bacteria to be fully susceptible to the antibiotic. These results were corroborated by studies performed with ['4C] gentamicin; binding of the labeled antibiotic by resting neutrophils, or by neutrophils ingesting live, killed S. aureus or endotoxin-coated paraffin particles, showed no statistical differences and never exceeded 20% of the extracellular concentration. These results show that intraleukocytic S. aureus are protected from the bactericidal action of gentamicin and suggest that this protection can be explained by poor intracellular penetration of the antibiotic.
Phagocytic uptake of opsonized bacteria, followed by their intracellular killing, is an important defence mechanism against several types of invasive bacterial infections (25) . These two groups of events, ingestion and intracellular killing, can be tested independently and have been shown to proceed at different time rates (25) . Thus, many virulent Staphylococcus aureus are promptly phagocytosed by polymorphonuclear leukocytes (PMN), but remain viable while intracellular for a prolonged period of time (16) .
The suggestion that such intracellular bacteria might be protected from the bactericidal effect of extracellular II products was already made in 1916 (17) , and was thereafter confirmed experimentally in phagocytic systems for several antibiotics (1, 10, 13, 14, 20, 22) .
Although aminoglycosidic antibiotics such as streptomycin or gentamicin are potent bactericidal agents against Staphylococcus aureus in a cell-free in vitro system, their effectiveness in clinical infections is by far not convincing (9, 12) . Emergence of variant forms after exposure to gentamicin offers only a partial explanation of this discrepancy, since their demonstration is rare in clinical isolates and inconstant during laboratory manipulation (15) . Direct evidence of the protection of S. aureus from gentamicin in the presence of phagocytic cells was therefore looked for in the present study by two different techniques. First, viability of ingested organisms in the presence of bactericidal concentrations of gentamicin was shown to be unaffected by the antibiotic. Second, binding or penetration of radioactive gentamicin to purified PMN or both was found to be low and unaffected by active ingestion oflive bacteria or inert particles. These results demonstrate the complete protection of ingested S. aureus from the bactericidal effect of gentamicin and allow us to postulate insufficient intraleukocytic penetration or availability of the antibiotic as one of the responsible mechaniisms.
METHODS
Bacterial strains. Staphylococcus aureus strain Wood 46 was used in the majority of the phagocytic experiments, its opsonic requirements being limited to alternative pathway-mediated complement activity (11) . The strain used was susceptible to gentamicin at a concentration of 0.1 pg/ml in Mueller-Hinton broth.
For the experiments measuring the binding of radioactive gentamicin, another gentamicin-resistant strain had to be used: this clinical isolate, obtained at the H6pital Cantonal Geneva and called MR-GR 1, was found to be also resistant to methicillin, erythromycin, tetracycline, and kanamycin. A Phagocytic bactericidal assays. Conditions used for the phagocytic assay were as follows: each 1-ml incubation mixture included 5 x 106 PMN in DGS medium and 2 x 106 to 6 x 106 colony-forming units (CFU) of strain S. aureus Wood 46 (0.1 ml from a 50-fold diluted overnight culture in Mueller-Hinton broth). Incubations were performed at 37°C in siliconized tubes in a horizontal shaker at a rate of 240/min. The hypotonic lysis procedure of the PMN at the end of the incubation was found to be harmful to staphylococci in the presence of gentamicin, even in trace amounts. In all phagocytic bactericidal assays performed in this study, a modified lysis procedure of PMN, which preserved bacterial viability, was devised by diluting 0.1-ml portions of the phagocytic mixture in 10 ml of isotonic saline supplemented with 0.1% Triton X-100. In such a medium, lysis of PMN was achieved within 2 min without any significant killing of S. aureus. After further isotonic 10-fold dilution, if required, portions of the most appropriate dilution were plated on Mueller-Hinton agar, and residual CFU were determined after incubation at 37°C up to 48 h. When lysostaphin was included in the phagocytic assay, the antibiotic was inactivated before lysis of PMN by preincubation of each 0.1-ml portion for 10 min at 37°C with 0.9 ml of a 0.25% trypsin solution in saline (26) ; inactivation of lysostaphin by trypsin treatment under our experimental conditions was confirned by negative residual antibiotic assays. Thereafter, the whole 1-ml portion was treated as described above.
To evaluate the effects of antibiotics on intracellular bacteria, ingestion had to be allowed to occur before addition of any antibacterial agent; this was achieved by a 10-min preincubation of opsonized bacteria and PMN. The bacterial killing rate of the system at 10 min was quantified by CFU counts as described above. After the 10 min of preincubation, either gentamicin or lysostaphin was added in 0.1-ml concentrated saline solutions. The kinetics of further bacterial killing were recorded by performing CFU counts at 10-min intervals. Each test was always run with controls lacking either the antimicrobial agent or the PMN.
Removal of one antimicrobial agent before addition of a second one was achieved by three centrifugations for 10 min at 300 x g, and washings in 0.1 ml of DGS of the suspension. PMN counts and viability studies showed an 80 to 100% recovery of the PMN, with more than 95% viability by the trypan blue exclusion test at the end of the procedure.
GENTAMICIN ACTIVITY IN HUMAN NEUTROPHILS lized in 0.5 ml of 0.8 N NaOH for 3 h, and portions of the dissolved material were mixed with 10 ml of an emulsion system selected for scintillation counting. period of incubation full activity ofthe antibiotic was recovered in the supematant of the centrifuged PMN-bacteria mixture by either a microbiological (4) or an enzymatic (21) assay. Since lysostaphin has been shown to be bactericidal for extraleukocytic S. aureus only (19, 26) in phagocytic assays, its effect was compared with that of gentamicin. Figure 2 shows that 5 ,ug of gentamicin per ml and 10 U of lysostaphin per ml, added separately to two phagocytic mixtures preincubated for 10 min with opsonized S. aureus and PMN, produced similar kill curves, the differences in CFU counts never exceeding 20% (n = 5). When tested in the absence of PMN, lysostaphin exerted a rapid killing effect on S. aureus which was complete at 5 min and reduced the CFU count by 1.3 to 1.7 log1o.
These results taken together showed that both gentamicin and lysostaphin were less efficient bactericidal agents in the presence of phagocytosing PMN, but still raised the question of 745 VOL. 16, 1979 on whether the poor antibacterial activity of gentamicin was indeed limited to intracellular organisms. This question was investigated by using the following experimental approach: PMN and S. aureus were incubated for 10 min as outlined previously, and lysostaphin was added at a concentration of 10 U/ml for a further 10 min. At 20 min, the incubation was divided into three portions. One received 5 ug of gentamicin per ml, the second received 50 ,g of gentamicin per ml, and the last one received saline (control tube). Figure 3 demonstrates that the addition of gentamicin, at concentrations as high as 50 ,ug/ml, to a phagocytic mixture already treated with lysostaphin, did not modify the progressive decrease in CFU counts recorded in the control tube and resulting from the bactericidal activity of PMN. No modification could be recorded either after 150 or 300 mim of incubation; in contrast, 0.6 utg of gentamicin per ml killed 3 logwo of S. aureus within 60 min in the absence of PMN (data not shown). In conclusion, gentamicin at 50 Ag/ml was totally ineffective against residual S. aureus after the removal of extracellular organisms by lysostaphin in the presence of phagocytosing PMN. This lack of killing effect could not be ascribed to inactivation of the antibiotic, since activity of each antimicrobial agent was assayed at the end of these experiments and found to be unchanged. Lysostaphin having been shown to be without bactericidal effect on intracellular organisms, these results suggested that gentamicin-"insensitive," were the phagocytized intracellular staphylococci.
To rule out any inhibitory effect oflysostaphin on the gentamicin bactericidal effect, the same experiment as recorded in Fig. 3 was repeated, except that the phagocytic suspension was washed free of lysostaphin before receiving either gentamicin or saline (Fig. 4) . At 20 mm, the lysostaphin-treated phagocytic suspension was centrifuged three times and suspended in fresh DGS medium. During the washing steps, CFU counts decreased from 6.6 x 10' to 3.0 x 104 CFU/ml, whereas PMN counts and viability remained unchanged. After the last wash, one tube received 5 ug of gentamicin, another one received 50 ,ug/ml, and the last portion received only saline (control tube). In the absence of lysostaphin, gentamicin at 50 or 5 ,ug/ml was as inactive against lysostaphin-treated, PMN-associated bacteria as saline (Fig. 4) .
Confirmation of the intraleukocytic location of the S. aureus surviving gentamicin treatment was attempted by the following experiments. After 60 min of incubation under experimental conditions identical to those depicted in Fig. 2  and 3 , the phagocytic suspensions were removed and their PMN were lysed by the addition of 1/ lysates including gentamicin were performed and shown to decrease by more than 2 log1o. (1, 10, 13, 14, 20, 22, 23) . Thus, no information regarding the initial penetration of antibiotics added to the phagocytic assay could be obtained, because the initial decrease in CFU reflected in part the elimination of the residual extraleukocytic bacteria by the antibiotic (1, 10, 13, 14, 20, 22, 23) . Ideally, such a system requires rapid and almost complete ingestion of the test bacteria, elimination of extracellular, noningested microorganisms, rapid killing effect of the antibiotic tested in a cell-free system, and delayed bactericidal contribution of the intracellular, PMN-dependent killing mechanisms. Our approach to evaluating the initial bactericidal effect of gentamicin on intraleukocytic S. aureus consisted of incubating the antibiotic with a phagocytic suspension after extensive ingestion followed by lysostaphin treatment, in such a way that CFU counts reflected mainly the viability of intraleukocytic bacteria. Previous studies from our laboratory have confirmed the findings of Bjorksten et al. (5) (5, 19, 26) .
Our present study shows that gentamicin added at a highly bactericidal concentration to preingested S. aureus exerts no killing effect on the population of intraleukocytic microorganisms. This inhibition of gentamicin killing effect was a long-lasting phenomenon, since no delayed killing occurred after several hours of incubation. Two parameters had to be checked carefully during these experiments. First, viability of the PMN was confirmed to remain constant for several hours of incubation, as checked by the dye exclusion test, and it was unaffected by the presence or absence of lysostaphin or gentamicin ANTIMICROB. AGENTS CHEMOTHER. or both. Furthermore, functional integrity of the PMN after several hours of incubation under similar experimental conditions has been documented by rechallenge experiments (27) . Second, it had to be demonstrated that extraleukocytic bactericidal activity of gentamicin remained constant throughout the experiments and was unaffected by PMN, since recent observations have suggested inactivation of aminoglycosidic antibiotics by inflammatory exudates (7) . The following observations suggest that gentamicin antibacterial activity was intact during the assay. (i) Full activity of the antibiotic was recovered at the end of the incubation period, as assayed by standard microbiological or enzymatic procedures (4, 21) . (ii) The impeded bactericidal activity of gentamicin in presence of a PMN suspension was restored after Triton X-100 lysis of the PMN, bringing the formerly intraleukocytic S. aureus into contact with the antibiotic. A possible interfering effect of lysostaphin on gentamicin bactericidal activity against intraleukocytic S. aureus was also excluded by appropriate control experiments, since gentamicin was still unable to kill intraleukocytic S. aureus after lysostaphin had been eliminated from the phagocytic suspension. Also, lysostaphin-treated S. aureus were still susceptible to added gentamicin (data not shown) in a cell-free system. Evaluation of gentamicin binding by PMN, whether resting or involved in active phagocytosis, was complicated by the high affinity of ['4C]gentamicin for unknown substrates resulting from PMN lysis. Traces (1%) of this material purposely contaminating the purified preparation of intact PMN increased significantly the radioactive counts of cell-associated [14C]gentamicin. This contribution was therefore difficult to quantify in our experiments, since a 1% lysis of PMN was undetectable by the dye exclusion test. The fact that high counts (10-to 100-fold) were recorded in a few assays only, whereas most showed low cell-associated radioactive counts, favors the interpretation that this artifact occurred only occasionally in our system. Further experiments (manuscript in preparation) suggest that this binding occurs on nuclear material. Even with this restriction, the maximal amount of radioactive gentamicin which entered the PMN can be estimated to be low; 107 PMN contain approximately 2 pl of intracellular water (14) , and 43 ng of gentamicin distributed in this volume could result in a final intracellular concentration of 21.5 ,gg/ml. This estimation is well below the 100-Ag/ml extraleukocytic concentration of ['4C]gentamicin used in our phagocytic system.
Our results allow us, therefore, to suggest that on August 14, 2017 by guest http://aac.asm.org/ Downloaded from gentamicin does not accumulate in the intracellular space of PMN and that its intracellular concentration is even lower than that expected from simple diffusion mechanisms. Poor diffusibility of charged molecules across eukaryotic cell membranes has been amply documented (18) , and such a principle seems to be valid for gentamicin also.
In conclusion, the inability of gentamicin to kill intraleukocytic S. aureus is due partly to its poor penetration into phagocytes. It is also conceivable that the low pH prevailing in the phagosome reduces the bactericidal activity of gentamicin as documented in a cell-free system (2). Finally, intraleukocytic S. aureus could become insensitive to gentamicin by a leukocyte-induced defect in its aerobic active transport mechanism (6), thus inhibiting the accumulation of bactericidal amounts of this antibiotic. All these factors acting together can contribute to the protection of intraleukocytic bacteria from gentamicin bactericidal action, as demonstrated in our study.
